Overview

Orgovyx is a medicine used to treat advanced cancer of the prostate (a gland of the male reproductive system) in adult patients when the cancer is ‘hormone-sensitive’, which means that it responds to treatments that reduce the levels of testosterone (the male sex hormone).

Orgovyx contains the active substance relugolix.

Orgovyx is available as tablets. The recommended dose is three tablets on the first day of treatment and then one tablet once a day taken around the same time each day.

The medicine can only be obtained with a prescription. For more information about using Orgovyx, see the package leaflet or contact your doctor or pharmacist.

The testicles produce testosterone which can make prostate cancer cells grow. The active substance in Orgovyx, relugolix, works by blocking a step in the process that signals the testicles to produce testosterone.

This step involves the release of a hormone called gonadotrophin-releasing hormone (GnRH) from the brain. By blocking the effects of GnRH, Orgovyx reduces the amount of testosterone in the body and slows down the growth of the prostate cancer cells.

A main study involving 934 men with advanced hormone-sensitive prostate cancer showed that Orgovyx is effective at reducing the amount of testosterone to levels seen in men whose testicles have been surgically removed.

During the first year, 97% of the patients receiving Orgovyx had the required reduction of testosterone levels, compared with 89% of patients receiving leuprorelin (another medicine for prostate cancer). These results showed that Orgovyx was as effective as leuprorelin.

The most common side effects with Orgovyx (which may affect more than 1 in 5 people) are hot flushes, muscle and joint pain and tiredness. Other very common side effects are diarrhoea and constipation.

For the full list of side effects and restrictions for Orgovyx, see the package leaflet.

The European Medicines Agency decided that Orgovyx’s benefits are greater than its risks and it can be authorised for use in the EU.

A main study showed that Orgovyx was as effective as standard treatment with another medicine (leuprorelin) in reducing testosterone levels of patients with advanced hormone-sensitive prostate cancer. Orgovyx was generally well-tolerated by most of the patients. Its side effects were mild and manageable.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orgovyx have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Orgovyx are continuously monitored. Suspected side effects reported with Orgovyx are carefully evaluated and any necessary action taken to protect patients.

Orgovyx received a marketing authorisation valid throughout the EU on 29 April 2022.

Orgovyx : EPAR - Medicine Overview

български (BG) (144.12 KB - PDF)
español (ES) (119.63 KB - PDF)
čeština (CS) (140.59 KB - PDF)
dansk (DA) (118.71 KB - PDF)
Deutsch (DE) (121.76 KB - PDF)
eesti keel (ET) (107.87 KB - PDF)
ελληνικά (EL) (140.87 KB - PDF)
français (FR) (119.83 KB - PDF)
hrvatski (HR) (140.48 KB - PDF)
italiano (IT) (118.93 KB - PDF)
latviešu valoda (LV) (149.04 KB - PDF)
lietuvių kalba (LT) (140.98 KB - PDF)
magyar (HU) (138.22 KB - PDF)
Malti (MT) (142.13 KB - PDF)
Nederlands (NL) (118.95 KB - PDF)
polski (PL) (144.76 KB - PDF)
português (PT) (119.91 KB - PDF)
română (RO) (139.62 KB - PDF)
slovenčina (SK) (140.74 KB - PDF)
slovenščina (SL) (139.56 KB - PDF)
Suomi (FI) (117.81 KB - PDF)
svenska (SV) (117.61 KB - PDF)

Orgovyx : EPAR - Risk management plan summary

Product information

Orgovyx : EPAR - Product Information

български (BG) (501.61 KB - PDF)
español (ES) (465.95 KB - PDF)
čeština (CS) (385.42 KB - PDF)
dansk (DA) (423.19 KB - PDF)
Deutsch (DE) (439.77 KB - PDF)
eesti keel (ET) (593.61 KB - PDF)
ελληνικά (EL) (502.09 KB - PDF)
français (FR) (464.12 KB - PDF)
hrvatski (HR) (400.67 KB - PDF)
íslenska (IS) (465 KB - PDF)
italiano (IT) (457.61 KB - PDF)
latviešu valoda (LV) (567 KB - PDF)
lietuvių kalba (LT) (811.06 KB - PDF)
magyar (HU) (461.35 KB - PDF)
Malti (MT) (530.63 KB - PDF)
Nederlands (NL) (443.85 KB - PDF)
norsk (NO) (450 KB - PDF)
polski (PL) (414.31 KB - PDF)
português (PT) (407.7 KB - PDF)
română (RO) (444.53 KB - PDF)
slovenčina (SK) (380.1 KB - PDF)
slovenščina (SL) (416.87 KB - PDF)
Suomi (FI) (420.42 KB - PDF)
svenska (SV) (441.63 KB - PDF)

Latest procedure affecting product information: N/0018

20/12/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Orgovyx : EPAR - All authorised presentations

български (BG) (88.82 KB - PDF)
español (ES) (83.52 KB - PDF)
čeština (CS) (86.11 KB - PDF)
dansk (DA) (83.54 KB - PDF)
Deutsch (DE) (84.89 KB - PDF)
eesti keel (ET) (253.61 KB - PDF)
ελληνικά (EL) (86.08 KB - PDF)
français (FR) (255.08 KB - PDF)
hrvatski (HR) (83.86 KB - PDF)
íslenska (IS) (85.06 KB - PDF)
italiano (IT) (83.66 KB - PDF)
latviešu valoda (LV) (85.82 KB - PDF)
lietuvių kalba (LT) (87.24 KB - PDF)
magyar (HU) (85.98 KB - PDF)
Malti (MT) (86.2 KB - PDF)
Nederlands (NL) (83.7 KB - PDF)
norsk (NO) (83.81 KB - PDF)
polski (PL) (85.71 KB - PDF)
português (PT) (254.58 KB - PDF)
română (RO) (85.75 KB - PDF)
slovenčina (SK) (87.72 KB - PDF)
slovenščina (SL) (83.83 KB - PDF)
Suomi (FI) (81.73 KB - PDF)
svenska (SV) (81.62 KB - PDF)

Product details

Name of medicine
Orgovyx
Active substance
relugolix
International non-proprietary name (INN) or common name
relugolix
Therapeutic area (MeSH)
Prostatic Neoplasms
Anatomical therapeutic chemical (ATC) code
L02BX

Pharmacotherapeutic group

Endocrine therapy

Therapeutic indication

Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Authorisation details

EMA product number
EMEA/H/C/005353

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Marketing authorisation holder
Accord Healthcare S.L.U.

Edificio Este Planta 6a
World Trade Center
Moll De Barcelona S/n
08039 Barcelona
SPAIN

Opinion adopted
24/02/2022
Marketing authorisation issued
29/04/2022
Revision
9

Assessment history

Orgovyx : EPAR - Procedural steps taken and scientific information after information

Orgovyx-H-C-PSUSA-00010994-202301 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Orgovyx : EPAR - Public Assessment Report

CHMP summary of positive opinion for Orgovyx

This page was last updated on

How useful do you find this page?